Program By Day

7:00 AM-7:55 AM

Complimentary Continental Breakfast

7:55 AM-9:00 AM

Welcome and General Session 7: Emerging Targets in Immunotherapy

Marka R. Crittenden, MD, PhD—Chair
Earle A. Chiles Research Institute, Providence Cancer Center

Jason J. Luke, MD, FACP—Chair
University of Chicago Comprehensive Cancer Center

Mary L. (Nora) Disis, MD, FASCO
University of Washington

Michael A. Postow, MD
Memorial Sloan Kettering Cancer Center
Newer T-Cell Checkpoint Inhibitors: Used Independently and in Combination with Currently Approved Checkpoint Inhibitors

Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute
IDO Inhibition: Inhibiting the Inhibitors in Ovarian Cancers


Katelyn T. Byrne, PhD
University of Pennsylvania
Optimal Approaches to Translating CD40 As a Target in Pancreatic Cancer

Panel Question and Answer

9:00 AM-9:45 AM

Keynote Lecture

Malcolm K. Brenner, MD, PhD
Baylor College of Medicine Texas Children's Hospital
Should We Target Solid Tumors With CARs or TCRs?


Panel Question and Answer

9:45 AM-10:15 AM Break
10:15 AM-11:30 AM

Oral Abstract Session C: Biomarkers and Inflammatory Signatures

Stephen Ansell, MD, PhD—Chair
Mayo Clinic


Antoni Ribas, MD, PhD—Chair
University of California Los Angeles Medical Center


Abstract 140: Association of the T-cell receptor landscape with survival in non-small cell lung cancer.
First author: Alexandre Reuben


Abstract 180: MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.
First author: Justin Balko, PhD, PharmD


Antoni Ribas, MD, PhD
University of California Los Angeles Medical Center


Abstract 103: Exploration of the cGAS-STING pathway in prostate cancer.
First author: Emma Reilly


Abstract 104: Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer.
First author: Anshuman Panda


Ezra Cohen MD, PhD
University of California, San Diego


Panel Question and Answer

11:30 AM-1:00 PM Complimentary Boxed Lunch
11:45 AM-12:45 PM Networking Roundtables
For more information on Networking Roundtables, please visit the Onsite Networking page.
1:00 PM-2:00 PM General Session 8: Biomarkers—Insights Into Mechanisms and Clinical Outcomes

Lisa H. Butterfield, PhD—Chair
University of Pittsburgh

James L. Gulley, MD, PhD, FACP—Chair
National Cancer Institute

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Multiplexed Immunohistochemistry: Insights into Immunotherapy Mechanism of Action

Carsten Denkert, MD, PhD
Charité Universitätsmedizin Berlin - Institut für Pathologie
Tumor Genomic Signatures As Predictors of Clinical Response

Bernard A. Fox, PhD
Earle A. Chiles Research Institute, Providence Cancer Center
Integrating the Immunoscore into Clinical Practice: Is It Ready for Prime Time?

Panel Question and Answer
2:00 PM-2:30 PM Break
2:30 PM-4:00 PM

General Session 9: Immune Therapies in Hematologic Malignancies—Strategies to Improve Efficacy and Reduce Toxicity

Stephen M. Ansell, MD, PhD—Chair
Mayo Clinic

Stephen Gottschalk, MD—Chair
St. Jude Children's Research Hospital

Stephen M. Ansell, MD, PhD—Chair
Mayo Clinic
Integration of Immune Checkpoint Inhibitors in Hematologic Malignancies

Marco L. Davila, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Targeting B-Cell Malignancies with CAR T Cells: Beyond FDA Approval

Stephen Gottschalk, MD
St. Jude Children's Research Hospital
The Future of Bispecifics for Hematologic Malignancies

Matthew J. Frigault, MD
Massachusetts General Hospital Cancer Center
How to Manage Cytokine Release Syndrome and Neurotoxicity Post CAR-T and Bite Therapy

Panel Question and Answer